Publication:
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma

dc.contributor.coauthorTas, Faruk
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorErtürk, Kayhan
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T23:58:37Z
dc.date.issued2021
dc.description.abstractBackground Late adjuvant therapy is the term to define the treatment administered following complete resection of metastatic or relapsed disease. Objective To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma. Methods Twenty-seven adult cutaneous melanoma patients whose relapses were completely resected were included in this study. Temozolomide was administered as follows: peroral, 200 mg/m(2) once daily for five consecutive days of a 28-day treatment cycle for six cycles. Results The median age was 55 years and men were predominant (74%). Median follow-up time was 23.6 months (range, 3.6-122.6 months). Any type of relapse occurred in 14 (51.9%) patients, and five patients relapsed while on chemotherapy. Almost all relapses (n = 13, 93%) occurred within the first two years of follow-up. The relapse rates were found 37.4 and 49.1% in the first and second years of follow-up, respectively. Moreover, after fifth year of onset of chemotherapy, relapse rate was found only 51.9%. The median relapse-free survival (RFS) was 12.9 months, and 1-, 2-, 3-, and 5-year RFS rates were 60, 46, 39, and 39%, respectively. The estimated median overall survival was 23.6 months. All patients survived first year (n = 27, 100%), and the overall survival rates for 2, 3, and 5 years were 81, 48, and 48%, respectively. Conclusion Single-agent temozolomide may be a rational and prudent option for late adjuvant therapy in melanoma patients if/when novel therapies, such as targeting and immune therapies, are not accessible or available.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue1
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume27
dc.identifier.doi10.1177/1078155220909426
dc.identifier.eissn1477-092X
dc.identifier.issn1078-1552
dc.identifier.scopus2-s2.0-85082109214
dc.identifier.urihttp://dx.doi.org/10.1177/1078155220909426
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15493
dc.identifier.wos524151100001
dc.keywordsTemozolomide
dc.keywordsMelanoma
dc.keywordsLate adjuvant therapy
dc.keywordsSurvival stage-III
dc.keywordsDouble-blind
dc.keywordsCombination
dc.keywordsIpilimumab
dc.keywordsPlacebo
dc.languageEnglish
dc.publisherSage Publications Ltd
dc.sourceJournal of Oncology Pharmacy Practice
dc.subjectOncology
dc.subjectPharmacology
dc.subjectPharmacy
dc.titleSingle-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0001-5804-6800
local.contributor.kuauthorErtürk, Kayhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files